Drug Profile
TNF-alpha processing inhibitor
Alternative Names: TAPI - Amgen; TNF-alpha protease enzyme inhibitor; Tumour necrosis factor-alpha protease inhibitorLatest Information Update: 23 Jun 2000
Price :
$50
*
At a glance
- Originator Amgen
- Class Anti-inflammatories
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Jun 2000 No-Development-Reported for Inflammation in USA (Unknown route)
- 21 Apr 1999 Immunex has exclusively licensed its TNF-alpha converting enzyme technology to Wyeth-Ayerst
- 14 Feb 1997 Preclinical development for Inflammation in USA (Unknown route)